Allergy drug and supplement face off in battle against cancer treatment bone pain
NCT ID NCT07300735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two oral medications—diosmin-hesperidin (a flavonoid supplement) and loratadine (an allergy drug)—to prevent bone pain caused by G-CSF, a drug that boosts white blood cells in blood cancer patients. Researchers will compare each drug alone and in combination against a control in 88 adults. The goal is to find a safe, effective way to ease this common side effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diosmin-Hesperidin and Loratadine
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent a common side effect of cancer treatment.
What could go wrong
This is a small, early-stage study. The drugs may not reduce pain better than existing options, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Alexandria University Hospitals
RECRUITINGAlexandria, 21532, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••